Symrise has announced significant clinical study results within its portfolio of Health Active Solutions.
Chondractiv Move, a four-in-one collagen-based solution for joint health and mobility, has been clinically demonstrated to support menopausal women in their active lifestyle.
It offers a natural, science-backed and unique composition for brands seeking to formulate nutraceutical products supporting women’s health and healthy ageing.
Chondractic Move was launched in response to the rising market of menopausal women.
The four-in-one natural and proven solution supports physical exercise and active lifestyles and was introduced earlier this year at the Vitafoods Europe tradeshow in Barcelona, Spain and at SupplySide Global taking place in Las Vegas, United States.
The innovative combination of hydrolysed chicken cartilage and patented rosehip extract features collagen type II, chondroitin sulfate, hyaluronic acid and polyphenols.
It supports women aged 40+ looking for regular healthy joint maintenance and early prevention of joint discomfort.
The solution is designed for food supplements and functional foods and beverages.
Supported by scientific data
Chondractiv Move demonstrated positive effects on the population most impacted by activity-related joint discomfort and/or pain: women aged 40+.
This group includes active women, working mothers, fitness beginners, those in sport recovery and women in peri-menopausal transition.
At the cellular level, Chondractiv Move acted on synovial cells by increasing components of cartilage and decreasing the levels of cartilage-degrading enzymes.
Eight weeks of supplementation with a low daily dose of 1.58 g of Chondractiv Move induced a significant decrease in pain related to physical activity in daily life.
The earliest positive results were measured between the second and the third week of supplementation.
According to Dr Lionel Noah, Healthy Ageing Senior Scientific Expert at Symrise: "The four-in-one solution provides a sustainable effect on joint structure by modulating cartilage and bone microenvironment, with evidence supported by in vitro results."
"We could objectively describe the magnitude of this effect as ‘large.’ Several other parameters help to confirm the observed benefit of Chondractiv Move for joint comfort and function."
Symrise will present the findings during a webinar on December 9, titled "Active Menopausal Women: New Clinical Evidence in Joint Health".